13 research outputs found
Additional file 2: of New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali
Contig pile-ups of the genome of 12 P. falciparum isolates from Mali aligned against the reference 3D7 genome. The genome assembly of each of the 12 isolates, represented by its constituent contigs (blue lines in between blue circles) is aligned against each of the 14 nuclear chromosomes of the reference P. falciparum 3D7 strain (black). The location of var gene sequences is shown (red) in both the 3D7 genome and the contigs aligned to it. (PDF 1608 kb
Mean 3D7 growth inhibition assay results by study day and group with 95% confidence intervals.
<p>Mean 3D7 growth inhibition assay results by study day and group with 95% confidence intervals.</p
Percentage of subjects with growth inhibition assay activity ≥15% against FVO parasites, and percentage seroconverting from below up to or above threshold 30 days after last vaccination and at one and two years after enrollment, by vaccine group.
<p>Percentage of subjects with growth inhibition assay activity ≥15% against FVO parasites, and percentage seroconverting from below up to or above threshold 30 days after last vaccination and at one and two years after enrollment, by vaccine group.</p
Mean FVO growth inhibition assay results by study day and group with 95% confidence intervals.
<p>Mean FVO growth inhibition assay results by study day and group with 95% confidence intervals.</p
Percentage of subjects with growth inhibition assay activity ≥15% against 3D7 parasites, and percentage seroconverting from below up to or above threshold 30 days after last vaccination and at one and two years after enrollment, by vaccine group.
<p>Percentage of subjects with growth inhibition assay activity ≥15% against 3D7 parasites, and percentage seroconverting from below up to or above threshold 30 days after last vaccination and at one and two years after enrollment, by vaccine group.</p
Mean FVO growth inhibition assay result, and change from baseline to 30 days after last vaccination and one and two years after enrollment, with standard deviation (SD), by vaccine group.
<p>Mean FVO growth inhibition assay result, and change from baseline to 30 days after last vaccination and one and two years after enrollment, with standard deviation (SD), by vaccine group.</p
MOESM1 of Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara
Additional file 1. Raw data set of the IgG and GIA responses for the phase 1 trial of PfAMA1 FVO [25-545] in Malians adults in Bandiagara
Serious adverse events experienced by all subjects (months 0–24, all randomized participants).
<p>Data are reported as: Number of participants with a serious adverse event (% [95% confidence interval]) among participants given at least one dose of vaccine.</p
Anemia experienced by all subjects (months 0–24, all randomized participants).
<p>Data are reported as incidence of participants with at least one episode of anemia per 100 person-years at risk (PYAR) with 95% confidence intervals (incidence per PYAR [95% confidence interval]) among participants given at least one dose of vaccine. Based on 331.2 PYAR for FMP2.1/AS02<sub>A</sub> group and 331.9 PYAR for control group. *P<0.05.</p
Allele-specific vaccine efficacy against <i>P. falciparum</i> malaria, intention-to-treat cohort.
<p>PYAR, Person Years At Risk. CI, confidence interval. ND, not done.</p>*<p>Efficacy was calculated as 1– hazard ratio obtained using Cox proportional hazards modeling.</p>†<p>Rate of malaria episodes per person-year at risk.</p>‡<p>Efficacy was calculated as 1– risk ratio obtained using Poisson regression.</p